The Panbio™ COVID-19 Antigen Self-Test is a single-use, in vitro (i.e. outside the body) visually read rapid immunoassay that uses a nasal swab specimen for the qualitative detection of nucleocapsid protein SARS-CoV-2 antigen (Ag). The Panbio™ COVID-19 Antigen Self-Test is intended to be used manually by users for self-testing in a private setting, to aid in the diagnosis of an active SARS-CoV-2 infection. Children under 14 years should be supported by an adult.
The Panbio™ COVID-19 Antigen Self-Test is a single-use, in vitro (i.e. outside the body) visually read rapid immunoassay that uses a nasal swab specimen for the qualitative detection of nucleocapsid protein SARS-CoV-2 antigen (Ag). The Panbio™ COVID-19 Antigen Self-Test is intended to be used manually by users for self-testing in a private setting, to aid in the diagnosis of an active SARS-CoV-2 infection. Children under 14 years should be supported by an adult.
AESKU COVID-19 Rapid Antigen Test is an immunological method that is using nasal swab specimen for the qualitative detection of SARS-CoV-2 antigens. It is able to detect the presence of certain COVID-19 variants (Omicron and Delta)^. AESKU COVID-19 Rapid Antigen Test is developed and made in Germany, being externally evaluated by ESfEQA and CE-certified, and is being used by multiple private hospitals in Hong Kong for detecting the presence of COVID-19. The rapid antigen test is easy and convenient, allowing users to perform the tests on their own, and results to be illustrated in 15 minutes. There are 2 sets of test device inside 1 pack, which allows double confirmation upon suspected positive cases. The test is eligible for people of all ages, and any person under 12 years should be accompanied by adults.
Our first batch of “AESKU Covid-19 Rapid Antigen Test” sales received an overwhelming response and were sold out. To safeguard your health and thanks for your ongoing support, the second batch will be up for grabs again at below discount price:
INDICAID® offers user-friendly rapid antigen test, which can be used anytime, anywhere without the need of special equipment or facility. It is designed for qualitative detection of antigens in direct nasal swab samples, where the intuitive visual result will be shown in 20 minutes. The product is developed in Hong Kong, and is authorized by EU CE and Hong Kong Government for use. Moreover, it is recognized by Residential Care Homes for the Elderly (RCHE), Residential Care Homes for Persons with Disabilities (RCHD) and marathon. The rapid antigen test is clinically validated with overall sensitivity and specificity at 96% and 99% respectively.
INDICAID® offers user-friendly rapid antigen test, which can be used anytime, anywhere without the need of special equipment or facility. It is designed for qualitative detection of antigens in direct nasal swab samples, where the intuitive visual result will be shown in 20 minutes. The product is developed in Hong Kong, and is authorized by EU CE and Hong Kong Government for use. Moreover, it is recognized by Residential Care Homes for the Elderly (RCHE), Residential Care Homes for Persons with Disabilities (RCHD) and marathon. The rapid antigen test is clinically validated with overall sensitivity and specificity at 96% and 99% respectively.